The DOI matches its Crossref record.
Carcinoembryonic Antigen, Squamous Cell Carcinoma Antigen, CYFRA 21-1, and Neuron-specific Enolase in Squamous Cell Lung Cancer Patients
Abstract
Background: Carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC-Ag), and CYFRA 21-1 are the most useful markers for non-small cell lung cancer (NSCLC), but neuron-specific enolase (NSE) is a tumor maker of choice for SCLC. The determination of NSE in NSCLC could allow selection of patients with neuroendocrine features. NSCLC patients whose tumors have neuroendocrine properties may be more responsive to chemotherapy; however, these tumors have been reported to be more aggressive. Tumor markers are not suitable for diagnosis; their principal applications are in monitoring of therapy and prognosis. Methods: Tumor markers were measured in 200 untreated patients with squamous cell lung cancer (SQC) and a reference group (n = 220; 124 healthy persons and 96 patients with nonmalignant lung disease). CEA and SCC-Ag were measured by microparticle enzyme immunoassays on Abbott AxSYM and IMx analyzers. CYFRA 21-1 and NSE were measured by electrochemiluminescence immunoassays on the Roche Elecsys 2010. Results: CEA, SCC-Ag, CYFRA 21-1, and NSE were increased above the cutoffs in 26%, 32%, 67%, and 28% of tested patients, respectively. The area under the ROC curve for CYFRA 21-1 was higher than those for CEA, SCC-Ag, and NSE (SQC vs controls). CYFRA 21-1 and CEA were significantly higher in advanced SQC than in early stages of disease (P <0.0001 and P <0.0004, respectively). In multivariate analysis of survival, CYFRA 21-1 was an independent but nonspecific prognostic factor in the operable group of SQC patients, whereas NSE was an independent prognostic factor in the advanced stages of disease. Conclusion: CYFRA 21-1 is an independent prognostic factor in earlier stages and NSE in the advanced stages of SQC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Current and Future Development in Lung Cancer Diagnosis
Nooreldeen, R., & Bach, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168661 · Cited by 931
Carcinoembryonic antigen (CEA) as tumor marker in lung cancer
Grunnet, M., & Sorensen, J. B. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2011.11.012 · Cited by 750
Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects
Isgrò, M. A., Bottoni, P., & Scatena, R. (2015) · Advances in Experimental Medicine and Biology · doi:10.1007/978-94-017-7215-0_9 · Cited by 575
Biofunctionalized two-dimensional Ti3C2 MXenes for ultrasensitive detection of cancer biomarker
Kumar, S., Lei, Y., Alshareef, N. H., Quevedo-Lopez, M. A., & Salama, K. N. (2018) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2018.08.076 · Cited by 463
Clinical utility of cytokeratins as tumor markers
Barak, V., Goike, H., Panaretakis, K. W., & Einarsson, R. (2004) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2004.05.009 · Cited by 382
Metadata
- Authors
- Kulpa, J., Wójcik, E., Reinfuss, M., & Kołodziejski, L.
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-11-01
- Volume
- 48
- Issue
- 11
- Pages
- 1931-1937
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W1896982762
- Cited by
- 242
- References
- 0
- FWCI
- 1.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Carcinoembryonic Antigen, Squamous Cell Carcinoma Antigen, CYFRA 21-1, and Neuron-specific Enolase in Squamous Cell Lung Cancer Patients. https://app.cochat.ai/papers/10.1093/clinchem/48.11.1931
- The paper
- Kulpa, J., Wójcik, E., Reinfuss, M., & Kołodziejski, L. (2002). Carcinoembryonic Antigen, Squamous Cell Carcinoma Antigen, CYFRA 21-1, and Neuron-specific Enolase in Squamous Cell Lung Cancer Patients. Clinical Chemistry. https://doi.org/10.1093/clinchem/48.11.1931
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.